David Belada
-
- Lymphoma Diagnosis and Treatment 146
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 85
- Oncology top 5%
- CAR-T cell therapy research 31
- Viral-associated cancers and disorders 29
- Neurology top 10%
- CNS Lymphoma Diagnosis and Treatment 18
-
- Monoclonal and Polyclonal Antibodies Research 23
-
- Lung Cancer Treatments and Mutations 19
-
- Cutaneous lymphoproliferative disorders research 11
- Co-authors
- Marek TrněnýAndrea JaníkováRobert PytlíkHeidi MócikováVít ProcházkaLukáš SmolejVít CamprMartin Šimkovič
- Journals
- Blood (43 papers)Hematological Oncology (19 papers)Journal of Clinical Oncology (17 papers)
- Partner nations
- CzechiaUnited StatesSpain
In The Last Decade
David Belada
150 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 55
- Pathology and Forensic Medicine 819
- Genetics 327
- Oncology 604
- Neurology 175
- Immunology 176
Countries citing papers authored by David Belada
This map shows the geographic impact of David Belada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Belada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Belada more than expected).
Fields of papers citing papers by David Belada
This network shows the impact of papers produced by David Belada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Belada. The network helps show where David Belada may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Belada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 12 | |
| 7 | 2023 | 3 | |
| 8 | 2023 | 13 | |
| 9 | 2020 | 0 | |
| 10 | 2017 | 9 | |
| 11 | Comparison Of Contrast-Enhanced Ct-Based Response With Pet Assessment After First-Line Therapy For Follicular Lymphoma In The Phase Iii Gallium Study | 2017 | 1 |
| 12 | 2017 | 0 | |
| 13 | 2017 | 20 | |
| 14 | IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY | 2015 | 2 |
| 15 | QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR'S CHOICE: MCL-002 (SPRINT) TRIAL | 2015 | 2 |
| 16 | Diagnostika a léčba Waldenströmovy makroglobulinemie | 2014 | 0 |
| 17 | Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study | 2011 | 12 |
| 18 | Pattern of infections observed during the maintenance phase in the PRIMA study | 2011 | 1 |
| 19 | Diffuse large B-cell lymphoma in a patient with hyper-IgEsyndrome: Successful treatment with risk-adaptedrituximab-based immunochemotherapy | 2010 | 2 |
| 20 | 2003 | 5 |
About David Belada
David Belada is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology, having authored 167 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (146 papers), Chronic Lymphocytic Leukemia Research (85 papers), CAR-T cell therapy research (31 papers), Viral-associated cancers and disorders (29 papers), Monoclonal and Polyclonal Antibodies Research (23 papers), Lung Cancer Treatments and Mutations (19 papers), CNS Lymphoma Diagnosis and Treatment (18 papers) and Cutaneous lymphoproliferative disorders research (11 papers). The work is most often cited by research in Pathology and Forensic Medicine (819 citations), Genetics (327 citations) and Oncology (604 citations). David Belada has collaborated with scholars based in Czechia, United States and Spain. Frequent co-authors include Marek Trněný, Andrea Janíková, Robert Pytlík, Heidi Móciková, Vít Procházka, Lukáš Smolej, Vít Campr, Martin Šimkovič, Jiří Mayer and Jiřı́ Mayer. Their work appears in journals such as Blood, Hematological Oncology, Journal of Clinical Oncology, Annals of Hematology and Leukemia Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.